MDxHealth SA
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About MDxHealth
Services-Medical Laboratories, SIC 8071
MDxHealth SA is a commercial-stage molecular diagnostics company that develops and provides clinical diagnostic testing solutions, specializing in prostate cancer diagnostics and urological clinical conditions. The company's core product offerings include Confirm mdx, Exo mdx, GPS mdx, Resolve mdx, and Monitor mdx. These diagnostic tests are primarily utilized by healthcare providers, including medical practices, institutions, and urologists who make diagnostic recommendations, while payments and reimbursements for these services are processed through commercial health insurance companies, patients, and governmental healthcare payor programs such as Medicare and Medicaid.
The company operates clinical testing and research facilities, including a CLIA-certified clinical laboratory acquired through its Exosome Diagnostics business, supported by information technology and specialized laboratory equipment. MDxHealth SA maintains corporate headquarters and principal executive offices in Herstal, Belgium, alongside corporate and executive offices in Irvine, California, and an additional operating corporate entity based in the Netherlands.
Summary of the business section of MDxHealth's latest annual report, written by StockData.
Company profile
Company
- Legal name
- MDxHealth SA
- Founded
- 2003
- Headquarters
- Herstal, C9
- Address
- Cap Business Center, Rue D'Abhooz, 31, B-4040 00000
- Phone
- (949) 271-9221
- Website
- mdxhealth.com
- Employees
- 364, Dec 31, 2025
- Industry
- Services-Medical Laboratories
- Incorporated in
- C9
- Auditor
- BDO Reviseurs dEntreprises SRL, Zaventem, Belgium
Stock & identifiers
- Ticker
- MDXH
- Exchange
- Nasdaq
- IPO date
- Nov 5, 2021
- Shares outstanding
- 51M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Emerging growth company
- Stock splits
- 1-for-10 reverse, Apr 30, 2024
- SEC CIK
- 1872529
- CUSIP
- B5950S113
- ISIN
- USB5950S1137
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael McGarrity | Chief Executive Officer, Director | 95,000 |
| Joseph Sollee | See Remarks | – |
| John Bellano | Chief Commercial Officer | – |
| Brendan OConnell | VP, Finance and Accounting | – |
| Ron Kalfus | Chief Financial Officer | – |
| Eric Bednarski | Director | 6,903,100 |
| MVM Partners, LLC | Director | 4,700,457 |
| Koen Hoffman | Director | – |
| Don M. Hardison | Director | – |
| Sanford Jay Siegel | Director | – |
| Hilde Windels | Director | – |
| Michael Holder | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 364 employees,”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 24, 2023 | Delisting | Notice of delisting from exchange (Form 25) |
| Nov 5, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 1, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |